Revision of Precautions

Memantine hydrochloride

February 17, 2015

Non-proprietary Name
memantine hydrochloride

Safety measure
Precautions should be revised in the package insert.

In the Clinically significant adverse reactions subsection of the Adverse reactions section, the following texts should be added (underlined parts are revised):

Hepatic function disorder and jaundice:
Hepatic function disorder and/or jaundice with elevations of aspartate aminotransferase (glutamate oxaloacetate transaminase), alanine aminotransferase (glutamate pyruvate transaminase), alkaline phosphatase, bilirubin, etc. may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be taken.

NOTE
• This drug is designated to prepare a Drug Guide for Patients.